Program
ponesimod
Also written as “Ponesimod”, “ACT-128800” and “Ponesimod 10 mg”.
Its studies are mostly in Multiple Sclerosis · Psoriasis · Colitis, Ulcerative · Bronchiolitis Obliterans Syndrome, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Johnson & Johnson | 140 open or running | phase 3since Apr 21, 2015 | Feb 26, 2009 | none ahead |
| Vanda Pharmaceuticals | 22 open or running | phase 3since Jan 20, 2026 | Jan 20, 2026 | Aug 2028phase 3 · NCT07362017 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 2 studies since Feb 26, 2009.
- Mar 24, 2010Phase 2 study in Multiple SclerosisJohnson & Johnson · NCT01093326 · 353 enrolled · United States, Austria, Bulgaria and more
- Sep 22, 2010Phase 2 study in PsoriasisJohnson & Johnson · NCT01208090 · 326 enrolled · Austria, Belgium, Bulgaria and more
- Jan 6, 2014Phase 1 study in Safety and TolerabilityJohnson & Johnson · NCT02029482 · 16 enrolled · United Kingdom
- Feb 19, 2014Phase 1 study in HealthyJohnson & Johnson · NCT02068235 · 17 enrolled · United Kingdom
- Apr 29, 2014Phase 1 study in PharmacokineticsJohnson & Johnson · NCT02126956 · 6 enrolled · Switzerland
- May 9, 2014Phase 1 study in HealthyJohnson & Johnson · NCT02136888 · 116 enrolled · United States
- Aug 21, 2014Phase 1 study in HealthyJohnson & Johnson · NCT02223832 · 20 enrolled · United States
- Apr 21, 2015Phase 3 study in Multiple SclerosisJohnson & Johnson · NCT02425644 · 1,133 enrolled · United States, Belarus, Bosnia and Herzegovina and more
- Apr 28, 2015Phase 2 study in Bronchiolitis Obliterans SyndromeJohnson & Johnson · NCT02461134 · 1 enrolled
- Aug 25, 2016Phase 3 study in Multiple SclerosisJohnson & Johnson · NCT02907177 · 136 enrolled · United States, Australia, Austria and more
- Jul 20, 2017Phase 3 study in Multiple SclerosisJohnson & Johnson · NCT03232073 · 877 enrolled · United States, Belarus, Bosnia and Herzegovina and more
- Sep 21, 2022Phase 1 study in HealthyJohnson & Johnson · NCT05552196 · 28 enrolled · Belgium
- Jan 20, 2026Vanda Pharmaceuticals's first study: phase 3 study in PsoriasisNew to Vanda PharmaceuticalsVanda Pharmaceuticals · NCT07362017 · 300 planned · United States
- Jun 30, 2026Phase 3 study in Colitis, UlcerativeVanda Pharmaceuticals · NCT07686081 · 150 planned · United States
Ahead
- Aug 2028Primary completion: phase 3 study in PsoriasisVanda Pharmaceuticals · NCT07362017
- Apr 2029Primary completion: phase 3 study in Colitis, UlcerativeVanda Pharmaceuticals · NCT07686081
TargetBeta
“An orally available sphingosine-1-phosphate receptor 1 (S1PR1, S1P1) agonist that acts as a functional antagonist, ”NCIt, by rule
“Sphingosine 1-phosphate receptor Edg-1 agonist”ChEMBL 37, by rule
Other programs on S1PR1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| fingolimodrule | Novartis | phase 4 | 55 |
| etrasimodrule | Pfizer | phase 3 | 21 |
| cenerimodrule | Viatris | phase 3 | 14 |
| mocravimodrule | Novartis | phase 3 | 5 |
Studies
All 16 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07686081Colitis, Ulcerative · United States | 3 | Recruiting | Vanda Pharmaceuticals | Apr 2029 | 150 |
| NCT07362017Psoriasis · United States | 3 | Recruiting | Vanda Pharmaceuticals | Aug 2028 | 300 |
| NCT05552196Healthy · Belgium | 1 | Completed | Johnson & Johnson | Mar 5, 2023 | 28 |
| NCT03232073Multiple Sclerosis · United States, Belarus, Bosnia and Herzegovina and more | 3 | Completed | Johnson & Johnson | Jan 16, 2024 | 877 |
| NCT02907177Multiple Sclerosis · United States, Australia, Austria and more | 3 | Terminated | Johnson & Johnson | Mar 26, 2020 | 136 |
| NCT02461134Bronchiolitis Obliterans Syndrome | 2 | Terminated | Johnson & Johnson | Mar 2, 2017 | 1 |
| NCT02425644Multiple Sclerosis · United States, Belarus, Bosnia and Herzegovina and more | 3 | Completed | Johnson & Johnson | May 16, 2019 | 1,133 |
| NCT02223832Healthy · United States | 1 | Completed | Johnson & Johnson | Apr 2009 | 20 |
| NCT02136888Healthy · United States | 1 | Completed | Johnson & Johnson | Feb 2012 | 116 |
| NCT02126956Pharmacokinetics · Switzerland | 1 | Completed | Johnson & Johnson | Apr 2009 | 6 |
| NCT02068235Healthy · United Kingdom | 1 | Completed | Johnson & Johnson | Nov 2014 | 17 |
| NCT02029482Safety and Tolerability · United Kingdom | 1 | Completed | Johnson & Johnson | Jun 2010 | 16 |
| NCT01208090Psoriasis · Austria, Belgium, Bulgaria and more | 2 | Completed | Johnson & Johnson | Oct 31, 2012 | 326 |
| NCT01093326Multiple Sclerosis · United States, Austria, Bulgaria and more | 2 | Completed | Johnson & Johnson | Sep 6, 2023 | 353 |
| NCT01006265Multiple Sclerosis · United States, Australia, Austria and more | 2 | Completed | Johnson & Johnson | Jun 1, 2011 | 464 |
| NCT00852670Plaque Psoriasis · Austria, France, Germany and more | 2 | Completed | Johnson & Johnson | Jul 2009 | 66 |
How it is read
Names in the registry
- “Ponesimod”, 6 entries
- “ACT-128800”, 5 entries
- “Ponesimod 10 mg”, 2 entries
- “Ponesimod 20 mg”, 2 entries
- “Ponesimod 40 mg”, 2 entries
Conditions, from the studies’ own filings
- Multiple Sclerosis, 5 studies
- Psoriasis, 3 studies
- Colitis, Ulcerative, 1 study
- Bronchiolitis Obliterans Syndrome, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.